Meeshanthini Dogan
Algemeen Directeur bij CARDIO DIAGNOSTICS HOLDINGS, INC.
Vermogen: 1 M $ op 31-05-2024
Actieve functies van Meeshanthini Dogan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CARDIO DIAGNOSTICS HOLDINGS, INC. | Directeur/Bestuurslid | 25-10-2022 | - |
Algemeen Directeur | 25-10-2022 | - | |
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Directeur/Bestuurslid | 01-05-2017 | - |
Algemeen Directeur | 01-05-2017 | - | |
Oprichter | 01-05-2017 | - |
Loopbaan van Meeshanthini Dogan
Opleiding van Meeshanthini Dogan
University of Iowa | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
Operationeel
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectoraal
Health Services | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CARDIO DIAGNOSTICS HOLDINGS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
- Beurs
- Insiders
- Meeshanthini Dogan
- Ervaring